<DOC>
	<DOCNO>NCT03007147</DOCNO>
	<brief_summary>This randomized phase III trial study well imatinib mesylate combination chemotherapy work treat patient newly diagnose Philadelphia chromosome positive acute lymphoblastic leukemia . Imatinib mesylate may stop growth cancer cell block enzymes need cell growth . Drugs use chemotherapy , work different way stop growth cancer cell , either kill cell , stop dividing , stop spread . Giving imatinib mesylate combination chemotherapy may work well treat patient Philadelphia chromosome positive acute lymphoblastic leukemia .</brief_summary>
	<brief_title>Imatinib Mesylate Combination Chemotherapy Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To compare disease-free survival ( DFS ) standard risk pediatric Philapdelphia chromosome ( Ph ) + acute lymphoblastic leukemia ( ALL ) treat continuous imatinib mesylate ( imatinib ) combine either high-risk Children 's Oncology Group ( COG ) /Berlin-Frankfurt-Munster ( BFM ) ALL chemotherapy backbone intensive European ( Es ) PhALL chemotherapy backbone . SECONDARY OBJECTIVES : I . To determine feasibility administration imatinib allogeneic hematopoietic stem cell transplantation ( HSCT ) high risk Ph+ ALL patient . II . To determine disease-free survival ( DFS ) high risk pediatric Ph+ ALL patient treat EsPhALL chemotherapy , HSCT first complete remission post-HSCT imatinib . III . To compare rate grade 3 high infection standard risk Ph+ ALL patient two randomized arm . TERTIARY OBJECTIVES : I . To describe toxicity associate post-HSCT administration imatinib . II . To evaluate long-term toxicity patient treat chemotherapy plus imatinib ( transplant ) , explore difference arm . III . To determine prognostic significance minimal residual disease ( MRD ) Ph+ ALL various time point therapy . IV . To determine prognostic significance MRD end Induction IA . V. To evaluate MRD post-Induction IB therapy standard risk ( SR ) patient explore whether difference randomize arm proportion patient non-detectable MRD time point . VI . To evaluate MRD high risk ( HR ) patient prior HSCT regular interval post-HSCT explore association measurement long-term outcome . VII . To evaluate concordance MRD assessment make immunoglobulin heavy chain ( IGH ) -T cell receptor ( TCR ) polymerase chain reaction ( PCR ) assay next generation sequencing ( NGS ) assay . VIII . To determine prognostic significance IKZF1 gene aberration deletion . IX . To determine frequency prognostic significance p210 BCR-ABL1 fusion variant pediatric Ph+ ALL . X . To measure adherence oral chemotherapeutic agent ( imatinib , 6-mercaptopurine , methotrexate ) 6 month maintenance phase standard risk Ph+ ALL patient . XI . To identify factor associate poor adherence . XII . To determine association relapse risk adherence oral chemotherapeutic agent ( separately combine ) . XIII . To measure adherence imatinib allogeneic HSCT high risk Ph+ ALL patient identify factor associate poor adherence . OUTLINE : INDUCTION IA PART 1 : Patients receive induction IA accord standard care day 1-14 . INDUCTION IA PART 2 : Patients receive imatinib mesylate orally ( PO ) daily ( QD ) day 15-33 , prednisolone PO twice daily ( BID ) methylprednisolone intravenously ( IV ) day 15-28 , vincristine sulfate IV 1 minute day 15 22 , daunorubicin hydrochloride IV 1-15 minute day 15 22 , methotrexate intrathecally ( IT ) day 29 . INDUCTION IB : Patients receive imatinib mesylate PO QD day 1-35 , cyclophosphamide IV 30-60 minute day 1 28 , mercaptopurine PO day 1-28 , cytarabine IV subcutaneously ( SC ) day 1-4 , 8-11 , 15-18 , 22-25 , methotrexate IT day 8 22 . POST-INDUCTION THERAPY : Patients standard risk randomize 1 2 arm . Patients high risk assign Arm C. ARM A : CONSOLIDATION BLOCK 1 : Patients receive imatinib mesylate PO QD day 1-21 , methotrexate IT , cytarabine IT , therapeutic hydrocortisone IT day 1 , high dose methotrexate IV 24 hour day 1 , vincristine sulfate IV 1 minute day 1 6 , dexamethasone PO BID IV day 1-5 , cyclophosphamide IV 30-60 minute day 2-4 , leucovorin calcium PO IV day 3 4 , high dose cytarabine IV 3 hour pegaspargase IV 1-2 hour day 5 , filgrastim SC day 7-11 absence disease progression unexpected toxicity . CONSOLIDATION BLOCK 2 : Patients receive imatinib mesylate PO QD day 1-21 , methotrexate IT , cytarabine IT , therapeutic hydrocortisone IT day 1 , high dose methotrexate IV 24 hour day 1 , dexamethasone PO BID IV day 1-5 , vincristine sulfate IV 1 minute day 1 6 , ifosfamide IV 1 hour mesna IV day 2-4 , leucovorin calcium PO IV day 3 4 , dexrazoxane hydrochloride IV 5-15 minute daunorubicin hydrochloride IV 1-15 minute day 5 , pegaspargase IV 1-2 hour day 6 , filgrastim SC day 7-11 absence disease progression unexpected toxicity . CONSOLIDATION BLOCK 3 : Patients receive imatinib mesylate PO QD day 1-21 , high dose cytarabine IV 3 hour day 1-3 , dexamethasone PO BID IV day 1-5 , etoposide IV 1-2 hour day 3-5 , methotrexate IT , cytarabine IT , therapeutic hydrocortisone IT day 5 , pegaspargase IV 1-2 hour day 6 , filgrastim SC day 7-11 absence disease progression unexpected toxicity . DELAYED INTENSIFICATION 1 PART 1 : Patients receive imatinib mesylate PO QD day 1-35 , methotrexate IT day 1 , dexamethasone PO BID IV day 1-7 15-21 , vincristine sulfate IV 1 minute , dexrazoxane hydrochloride IV 5-15 minute , doxorubicin IV 1-15 minute day 8 , 15 , 22 , 29 , pegaspargase IV 1-2 hour day 8 absence disease progression unexpected toxicity . DELAYED INTENSIFICATION 1 PART 2 : Patients receive imatinib mesylate PO QD day 36-63 , cyclophosphamide IV 30-60 minute day 36 , thioguanine PO day 36-49 , cytarabine IV 1-30 minute SC day 36-39 43-46 , methotrexate IT day 36 43 absence disease progression unexpected toxicity . INTERIM MAINTENANCE : Patients receive imatinib mesylate PO QD day 1-28 , methotrexate PO day 1 , 8 , 15 , 22 , mercaptopurine PO day 1-28 absence disease progression unexpected toxicity . DELAYED INTENSIFICATION 2 PART 1 : Patients receive imatinib mesylate PO QD day 1-35 , methotrexate IT day 1 , dexamethasone PO BID IV day 1-7 15-21 , vincristine sulfate IV 1 minute , dexrazoxane hydrochloride IV 5-15 minute , doxorubicin IV 1-15 minute day 8 , 15 , 22 , 29 , pegaspargase IV 1-2 hour day 8 absence disease progression unexpected toxicity . DELAYED INTENSIFICATION 2 PART 2 : Patients receive imatinib mesylate PO QD day 36-49 , cyclophosphamide IV 30-60 minute day 36 , thioguanine PO day 36-49 , cytarabine IV 1-30 minute SC day 36-39 43-46 , methotrexate IT day 36 43 absence disease progression unexpected toxicity . MAINTENANCE : Patients receive imatinib mesylate PO QD day 1-84 , methotrexate PO weekly ( QW ) IT day 1 43 course 1 , 2 , 3 , mercaptopurine PO day 1-84 . Courses imatinib mesylate mercaptopurine repeat every 84 day 104 week start Induction IA absence disease progression unexpected toxicity . ARM B : INTERIM MAINTENANCE : Patients receive imatinib mesylate PO QD day 1-63 , vincristine sulfate IV 1 minute high dose methotrexate IV 24 hour day 1 , 15 , 29 , 43 , leucovorin calcium PO IV day 3 4 , mercaptopurine PO day 1-56 , methotrexate IT day 1 29 absence disease progression unexpected toxicity . DELAYED INTENSIFICATION PART 1 : Patients receive imatinib mesylate PO QD day 1-28 , methotrexate IT day 1 , dexamethasone PO BID IV day 1-7 15-21 , vincristine sulfate IV 1 minute , dexrazoxane hydrochloride IV 5-15 minute , doxorubicin IV 1-15 minute day 1 , 8 , 15 , pegaspargase IV 1-2 hour day 4 absence disease progression unexpected toxicity . DELAYED INTENSIFICATION PART 2 : Patients receive imatinib mesylate PO QD day 29-56 , cyclophosphamide IV 30-60 minute day 29 , thioguanine PO day 29-42 , cytarabine IV 1-30 minute SC day 29-32 36-39 , methotrexate IT day 29 36 , vincristine sulfate IV 1 minute day 43 50 , pegaspargase IV 1-2 hour day 43 absence disease progression unexpected toxicity . INTERIM MAINTENANCE WITH CAPIZZI METHOTREXATE : Patients receive imatinib mesylate PO QD day 1-56 , vincristine sulfate IV 1 minute methotrexate IV 2-15 minute day 1 , 11 , 21 , 31 , 41 , methotrexate IT day 1 31 , pegaspargase IV 1-2 hour day 2 22 absence disease progression unexpected toxicity . MAINTENANCE : Patients receive imatinib mesylate PO QD day 1-84 , vincristine sulfate IV 1 minute day 1 , 29 , 57 , prednisolone PO BID ( methylprednisolone IV course 1 2 ) day 1-5 , 29-33 , 57-61 , mercaptopurine PO day 1-84 , methotrexate PO QW , methotrexate IT day 1 ( day 29 course 1 2 ) . Courses repeat every 84 day 104 week start Induction IA absence disease progression unexpected toxicity . ARM C : CONSOLIDATION BLOCK 1 : Patients receive imatinib mesylate , methotrexate , cytarabine , therapeutic hydrocortisone , high dose methotrexate , vincristine sulfate , dexamethasone , leucovorin calcium , high dose cytarabine , pegaspargase Arm A Consolidation Block 1 , filgrastim SC day 7 absence disease progression unexpected toxicity . CONSOLIDATION BLOCK 2 : Patients receive imatinib mesylate , methotrexate , cytarabine , therapeutic hydrocortisone , high dose methotrexate , dexamethasone , vincristine sulfate , ifosfamide , leucovorin calcium , dexrazoxane hydrochloride , daunorubicin hydrochloride , pegaspargase , filgrastim Arm A Consolidation Block 2 absence disease progression unexpected toxicity . CONSOLIDATION BLOCK 3 : Patients receive imatinib mesylate , dexamethasone , etoposide , methotrexate , cytarabine , therapeutic hydrocortisone , pegaspargase , filgrastim Arm A Consolidation Block 3 , high dose cytarabine IV 3 hour day 1-2 absence disease progression unexpected toxicity . HSCT : Patients undergo HSCT day 0 . Patients proceed HSCT receive Delayed Intensification 1 , Interim Maintenance , Delayed Intensification 2 , Maintenance Arm A. POST-HSCT : Patients receive imatinib mesylate PO QD start day 56-365 absence disease progression unexpected toxicity . After completion study treatment , patient follow every year 3 year .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Philadelphia Chromosome</mesh_term>
	<mesh_term>Neoplasm , Residual</mesh_term>
	<mesh_term>Precursor T-Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Hydrocortisone 17-butyrate 21-propionate</mesh_term>
	<mesh_term>Cortisol succinate</mesh_term>
	<mesh_term>Hydrocortisone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Hydrocortisone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<mesh_term>Isophosphamide mustard</mesh_term>
	<mesh_term>Pegaspargase</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<mesh_term>Asparaginase</mesh_term>
	<mesh_term>6-Mercaptopurine</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<mesh_term>Dexrazoxane</mesh_term>
	<mesh_term>Razoxane</mesh_term>
	<mesh_term>Thioguanine</mesh_term>
	<mesh_term>Podophyllotoxin</mesh_term>
	<mesh_term>Calcium , Dietary</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>2-Aminopurine</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<mesh_term>Folic Acid</mesh_term>
	<mesh_term>Mesna</mesh_term>
	<criteria>Patients previously enrol AALL08B1 APEC14B1 ( open classification newly diagnose ALL patient ) prior enrollment AALL1631 , baseline diagnostic sample must available develop MRD probe Newly diagnose de novo ALL ( BALL TALL ) definitive evidence BCRABL1 fusion karyotype , fluorescence situ hybridization ( FISH ) and/or reverse transcriptase ( RT ) PCR For patient DO NOT enter AALL1631 via AALL08B1 APEC14B1 ( open classification newly diagnose ALL patient ) , laboratory report detail evidence BCRABL1 fusion must submit rapid central review within 72 hour study enrollment Patients know chronic myelogenous leukemia ( CML ) develop lymphoid blast crisis eligible Patient must previously start induction therapy , include vincristine , corticosteroid , pegaspargase , without anthracycline , and/or standard cytotoxic chemotherapy Patient receive 14 day induction therapy Patient prior treatment imatinib , dasatinib , BCRABL1 inhibitor Karnofsky/Lansky performance status &gt; = 60 ; use Karnofsky patient &gt; 16 year age Lansky patient = &lt; 16 year age Direct bilirubin = &lt; 2.0 mg/dL Shortening fraction &gt; = 27 % echocardiogram Ejection fraction &gt; = 50 % radionuclide angiogram echocardiogram Corrected QT interval , QTc &lt; 480 msec Note : Repeat echocardiogram require echocardiogram obtain within 21 day study enrollment Creatinine clearance radioisotope glomerular filtration rate ( GFR ) &gt; = 70 mL/min/1.73 m^2 Serum creatinine within normal limit base age/gender , follow : 1 &lt; 2 year : maximum serum creatinine 0.6 mg/dL ( male female ) 2 &lt; 6 year : maximum serum creatinine 0.8 mg/dL ( male female ) 6 &lt; 10 year : maximum serum creatinine 1 mg/dL ( male female ) 10 &lt; 13 year : maximum serum creatinine 1.2 mg/dL ( male female ) 13 &lt; 16 year : maximum serum creatinine 1.5 mg/dL ( male ) , 1.4 mg/dL ( female ) &gt; = 16 year : maximum serum creatinine 1.7 mg/dL ( male ) , 1.4 mg/dL ( female ) Known history chronic myelogenous leukemia ( CML ) ALL develop previous cancer treat cytotoxic chemotherapy Active , uncontrolled infection , active systemic illness require ongoing vasopressor support mechanical ventilation Down syndrome Pregnancy breast feed Female patient pregnant ; pregnancy test require female patient childbearing potential Lactating female plan breastfeed infant Sexually active patient reproductive potential agree use effective contraceptive method duration study participation Patients congenital long QT syndrome , history ventricular arrhythmias heart block All patient and/or parent legal guardian must sign write informed consent All institutional , Food Drug Administration ( FDA ) , National Cancer Institute ( NCI ) requirement human study must meet</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>